4,6-二氨基-2-甲基巯基嘧啶 | 1005-39-6

• 物质功能分类: 医药中间体 - 杂环化合物 - 嘧啶类化合物
• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 中文名称: 4,6-二氨基-2-甲基巯基嘧啶
• 中文别名: 4,6-二氨基-2-甲巯基嘧啶
• 英文名称: 4,6-diamino-2-methylthiopyrimidine
• 英文别名: 2-(methylthio)pyrimidine-4,6-diamine；2-methylthio-4,6-diaminopyrimidine；4,6-Diamino-2-methylthio-pyrimidin；2-methylsulfanylpyrimidine-4,6-diamine
• CAS: 1005-39-6
• 化学式: C₅H₈N₄S
• mdl: MFCD00023241
• 分子量: 156.211
• InChiKey: AHAIUNAIAHSWPG-UHFFFAOYSA-N

物化性质

• 熔点：
  189-193 °C
• 沸点：
  413.5±25.0 °C(Predicted)
• 密度：
  1.38±0.1 g/cm3(Predicted)
• 稳定性/保质期：

  常温常压下稳定，避免与强氧化剂接触。

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  103
• 氢给体数：
  2
• 氢受体数：
  5

安全信息

• 危险等级：
  6.1
• 危险品标志：
  Xn
• 安全说明：
  S22,S24/25,S26,S36/37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  2933599090
• 危险品运输编号：
  UN 2811
• 包装等级：
  III
• 危险类别：
  6.1
• 危险性防范说明：
  P261,P301+P312,P302+P352,P304+P340,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  请将容器密封保存，并储存在阴凉干燥的地方。

SDS

Name:	4 6-Diamino-2-methylmercaptopyrimidine 98% Material Safety Data Sheet
Synonym:	None Known
CAS:	1005-39-6

Section 1 - Chemical Product MSDS Name:4 6-Diamino-2-methylmercaptopyrimidine 98% Material Safety Data Sheet
Synonym:None Known

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
1005-39-6	4,6-Diamino-2-methylmercaptopyrimidine	98%	213-735-9

Hazard Symbols: XN
Risk Phrases: 22 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Harmful if swallowed. Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation. May cause chemical conjunctivitis.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
Harmful if swallowed. May cause irritation of the digestive tract.
Inhalation:
Causes respiratory tract irritation. May be harmful if inhaled.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Clean up spills immediately, observing precautions in the Protective Equipment section. Avoid generating dusty conditions.
Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Minimize dust generation and accumulation. Avoid breathing dust, vapor, mist, or gas. Avoid contact with eyes, skin, and clothing.
Keep container tightly closed. Avoid ingestion and inhalation. Use with adequate ventilation. Wash clothing before reuse.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 1005-39-6: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Crystalline powder
Color: light yellow
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 189 - 193 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C5H8N4S
Molecular Weight: 156.21

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable at room temperature in closed containers under normal storage and handling conditions.
Conditions to Avoid:
Incompatible materials, dust generation, excess heat.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Carbon monoxide, oxides of nitrogen, oxides of sulfur, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 1005-39-6 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
4,6-Diamino-2-methylmercaptopyrimidine - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.
Hazard Class: 6.1
UN Number: 2811
Packing Group: III
IMO
Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.
Hazard Class: 6.1
UN Number: 2811
Packing Group: III
RID/ADR
Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.
Hazard Class: 6.1
UN Number: 2811
Packing group: III

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XN
Risk Phrases:
R 22 Harmful if swallowed.
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
WGK (Water Danger/Protection)
CAS# 1005-39-6: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 1005-39-6 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 1005-39-6 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4,6-二氨基-2-甲基巯基嘧啶 在 盐酸 、 sodium hydroxide 、 N-溴代丁二酰亚胺(NBS) 、 氨基磺酸铵 、 sodium nitrite 作用下， 反应 2.25h， 生成 4-(7-Amino-5-methylsulfanyl-[1,2,3]triazolo[4,5-d]pyrimidin-2-yl)-N-(5-methyl-isoxazol-3-yl)-benzenesulfonamide
  参考文献：
  名称：

  Application of fluorescent triazoles to analytical chemistry. I. Determination of aromatic primary amine with 2,4,6-triaminopyrimidine as a reagent.

  摘要：

  本研究开发了一种测定芳香族伯胺的灵敏荧光测定法。该方法先将氨基重氮化，然后与 2，4，6-三氨基嘧啶（TAP）偶联，得到的偶氮化合物被氧化成荧光三唑。利用各种嘧啶合成了取代的三唑，并对其荧光特性进行了评估。TAP 被选为最灵敏的试剂。在 2 位被取代的嘧啶中，没有一种能发出荧光。建立了磺胺甲噁唑（SMX）的测定方法（定量限：40 纳克/毫升）。这种方法比以前报道的方法更实用、更简单：通过一锅反应就能在一个烧瓶中获得最终的测定溶液。讨论了三唑环取代基对荧光的影响。

  DOI：

  10.1248/cpb.33.4928
• 作为产物：
  描述：

  4-氨基-6-氯-2-甲硫基嘧啶 在 氨 作用下， 以 甲醇 为溶剂， 反应 168.0h， 以29%的产率得到4,6-二氨基-2-甲基巯基嘧啶
  参考文献：
  名称：

  咪唑并吡啶-和嘌呤-硫代乙酰胺衍生物：核苷酸焦磷酸酶/磷酸二酯酶1（NPP1）的强抑制剂。

  摘要：

  核苷酸焦磷酸酶/磷酸二酯酶1（NPP1）属于胞外核苷酸酶家族，可控制细胞外核苷酸，核苷和（di）磷酸盐的水平。为了研究具有药物样特性的NPP1强效和选择性抑制剂的（病理）生理作用。因此，使用比色测定法以对硝基苯基5'-胸苷单磷酸酯（p -Nph-5'-TMP）作为人工底物，筛选化合物库中的NPP1抑制剂。这导致发现2-（3 H-咪唑并[4,5 - b ]吡啶-2-基硫基）-N-（3,4-二甲氧基苯基）乙酰胺（5a）为具有K i的命中化合物。值为217 nM。随后的结构-活性关系研究导致了嘌呤和咪唑并[4,5- b ]吡啶类似物的开发，用p -Nph-5'-进行测定具有高抑制力（K i值分别为5.00 nM和29.6 nM）。以TMP为底物。出乎意料的是，与ATP作为底物相比，测试时这些化合物的效力明显较低，K i值在低微摩尔范围内。对原型抑制剂的抑制机理进行了研究，发现该抑制剂与两种底物都具有竞争性。

  DOI：

  10.1021/jm501434y

文献信息

• 5-ARYL-SUBSTITUTED DIHYDROPYRIDOPYRIMIDINES AND DIHYDROPYRIDAZINES AND USE THEREOF AS MINERAL CORTICOID ANTAGONISTS
  申请人：Figueroa Perez Santiago

  公开号：US20100035902A1

  公开（公告）日：2010-02-11

  The present application relates to novel aryl-substituted heterobicyclic compounds, a process for their preparation, their use for the treatment and/or prophylaxis of diseases, and their use for the manufacture of medicaments for the treatment and/or prophylaxis of diseases, especially cardiovascular disorders.

  本申请涉及新颖的芳基取代杂双环化合物，其制备方法，它们用于治疗和/或预防疾病的用途，以及它们用于制造治疗和/或预防疾病的药物，特别是心血管疾病。
• Synthesis and Antimicrobial Activity of Novel [(3-Aminopyrimidiniumyl)thio]methyl Cephalosporins
  作者：Yong-Zu Kim、Jong-Chan Lim、Jae-Hong Yeo、Chan-Sik Bang、Won-Sup Kim、Sam-Sik Kim、Yong-Min Woo、Duck-Ho Yang、Hunseung Oh、Keepyung Nahm

  DOI：10.1021/jm00048a018

  日期：1994.10

  A series of novel cephalosporin compounds which have 3-[(aminopyrimidiniumyl)thio]methyl substituents was synthesized. They show high antimicrobial activity against various bacterial species including Pseudomonas aeruginosa. Structure-activity relationships with various thiopyrimidines, thiopyrimidiniums, bicyclic thiotriazolopyrimidiniums, and bicyclic thioimidazolopyrimidiniums as 3'-substituents

  合成了一系列具有3-[（氨基嘧啶基）硫基]甲基取代基的新型头孢菌素化合物。它们对包括铜绿假单胞菌在内的各种细菌显示出很高的抗菌活性。还研究了与各种硫代嘧啶，硫代嘧啶，双环硫代三唑并嘧啶鎓和双环硫代咪唑并嘧啶鎓作为3'-取代基的结构活性关系；具有季铵化嘧啶鎓部分的头孢菌素比中性嘧啶头孢菌素具有更好的抗菌活性，并且使嘧啶鎓部分上的正电荷稳定对于更好的活性至关重要。根据半经验的PM3计算，嘧啶鎓环上的氨基和烷硫基取代基在电荷稳定和离域中起主要作用。
• Novel cephalosporin compounds and processes for the preparation thereof
  申请人：LUCKY LTD.

  公开号：EP0584797A3

  公开（公告）日：1994-06-08

  The present invention relates to novel cephalosporin compounds, pharmaceutically acceptable non-toxic salts, physiologically hydrolyzable esters, hydrates and solvates and isomers thereof which possess potent and broad antibacterial activities. The compounds of the present invention have a (1,5,6-substituted-4-aminopyrimidinium-2-yl)thiomethyl group in 3-position of the cephem nucleus and is specifically represented by the following formula(I):

  本发明涉及新型头孢菌素化合物，药学上可接受的无毒盐、生理可水解的酯、水合物和溶剂合物及其异构体，具有强大和广泛的抗菌活性。本发明的化合物在头孢菌素核的3位具有(1,5,6-取代-4-氨基嘧啶-2-基)硫甲基基团，具体由以下式(I)表示：
• Docking studies and development of novel 5-heteroarylamino-2,4-diamino-8-chloropyrimido-[4,5-b]quinolines as potential antimalarials
  作者：Advait A. Joshi、C.L. Viswanathan

  DOI：10.1016/j.bmcl.2006.02.038

  日期：2006.5

  MOE-Dock (Docking software) was used to predict the binding modes of 10 novel and potent 5-substituted amino-2,4-diamino-8-chloropyrimido-[4,5-b]quinolines (compounds I-X) as part of our antimalarial drug development programme. This was done by analyzing the interaction of these compounds with the active sites of 11 enzymes present in Plasmodium falciparum and based on this, effective binding was observed

  我们使用MOE-Dock（Docking软件）来预测10种新颖且有效的5-取代的氨基-2,4-二氨基-8-氯嘧啶基-[4,5-b]喹啉（化合物IX）的结合模式抗疟疾药物开发计划。通过分析这些化合物与恶性疟原虫中存在的11种酶的活性位点之间的相互作用来完成此操作，并据此观察到与恶性疟原虫谷胱甘肽还原酶（PfGR）的有效结合。化合物IX与PfGR的结合分数也与其抗疟活性一致。然后，根据上述对接研究和该类别的药效学要求，设计并合成了三个其他类似物。
• Synthesis, Dihydrofolate Reductase Inhibition, Anti-proliferative Testing, and Saturation Transfer Difference 1H-NMR Study of Some New 2-Substituted-4,6-diaminopyrimidine Derivatives
  作者：Shohreh Mohebbi、Juan Manuel Falcón-Pérez、Esperanza González、Oscar Millet、Jose Maria Mato、Farzad Kobarfard

  DOI：10.1248/cpb.60.70

  日期：——

  A series of 2-substituted-4,6-diaminipyrimidine derivatives were synthesized and evaluated for their dihydrofolate reductase (DHFR) inhibitory activity. Saturation transfer difference (STD) 1H-NMR experiments were used to probe the binding characteristics of the compounds with human DHFR enzyme. The most potent molecules, 12 and 15, in enzyme assay study showed the best results in STD experiments indicating their intimate interaction with the receptor. The docking studies were followed to explain the structural basis for the observed interaction between the ligands and DHFR. All the compounds were also assayed in vitro for their growth inhibitory activity on MCF-7, HepG2, SKHep1, and Hela tumor cell lines. Compounds 16, 17, and 22 demonstrated the most potent in vitro anti-proliferative activity among the others.

  合成了一系列2-取代-4,6-二氨基嘧啶衍生物并评估了它们的二氢叶酸还原酶（DHFR）抑制活性。饱和转移差(STD)1H-NMR实验用于探测化合物与人DHFR酶的结合特性。在酶测定研究中最有效的分子 12 和 15 在 STD 实验中显示出最好的结果，表明它们与受体的密切相互作用。随后进行对接研究，以解释观察到的配体和 DHFR 之间相互作用的结构基础。还在体外测定了所有化合物对 MCF-7、HepG2、SKHep1 和 Hela 肿瘤细胞系的生长抑制活性。化合物 16、17 和 22 在其他化合物中表现出最有效的体外抗增殖活性。

表征谱图